PTO/SB/08A (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

of 5

(Use as many sheets as necessary)

Complete if Known			
Application Number	10/535,608		
Filing Date	November 19, 2003		
First Named Inventor Hasan Kulaksiz			
Art Unit	1641		
Examiner Name	Gary W. Counts		
Attorney Docket Number	26605.00001		

Examiner	Cite	Document Number	Publication Date	Name of Patentee or	T Dance Columns Lines Mines
Initials*	No.1	Number-Kind Code ^{2 (Khooke)}	MM-DD-YYYY	Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	Α	US- 5,420,016	05/30/1995	Boguslaski et al.	
	В	^{US-} 2005/0037971	02-17-2005	Nicolas et al.	"
	С	US- 2004/0234527	11-25-2004	Crisanti, Andrea	
	D	US- 2003/0027999	02-06-2003	Rosen et al.	
	Е	^{US-} 2002/0091247	07-11-2002	Kaser et al.	.]
		US-			
		US-			1
		US-			·
		US-			
		US-			
		US-			
		US-		i i	"
		US-			1
		US-			1

	FOREIGN PATENT DOCUMENTS						
Examiner Cite Initials* No.		Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages		
		Country Code ³ "Number ⁴ "Kind Code ⁶ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T⁵	
	F	WO02/098444	12-12-2002	INSTITUT NATIONAL DE			
	G	WO00/73454	12/07-2000	GENETECH, INC.			
						_	
						Щ	

Examiner	Date	
Signature	Considered	

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through dilation if not in conformance and not considered, include copy of this form with next communication to applicant. "Applicant's unique citation designation number (optional). "See Knick Godes of USPTO Palent Documents at year-year-good, over MPEP 901-04." Either Clinic that issued the document, by the wick-lefts code (WPO Standard ST.3.)" For Japanese patent documents, the indication of the year of the reign of the Emperor must procede the senial number of the patent comment. "Kind of document by the appropriate symbols as indicated on the document node WPO Standard ST.1.6 if yossible." "Applicant is to place a check mark here!" English language. Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tademank Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO TIME. TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known Substitute for form 1449/PTO Application Number 10/535,608 INFORMATION DISCLOSURE Filing Date November 19, 2003 STATEMENT BY APPLICANT First Named Inventor Hasan Kulaksiz Art Unit 1641 (Use as many sheets as necessary) Examiner Name Gary W. Counts Attorney Docket Number Sheet 2 15 26605.00001 of

		NON PATENT LITERATURE DOCUMENTS	
	н	NEMETH et al., "Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein," BLOOD (1 April 2003): Vol. 101, No. 7, pp.: 2461-2463	
	1	WILD, The Immunoassay Handbook, Stockton Press, 1994, pp. 66	
	J	DIAMANDIS et al, Immunoassay, Academic Press, Chapter 11, The Avidin-Biotin System (1996), pp. 237-255	
	к	BRUGNARA, Carlo, "Iron deficiency and erythropoiesis: New Diagnostic Approaches," Climincal chemistry 2003; Vol.: 49, No.: 10, pp. 1573-1578	
	L	SWINKLES et al., "Hereditary hemochromatosis: genetic complexity and new diagnostic approaches," Clinical chemistry 2006; Vol.: 52, No.: 6, pp. 950-968	
	м	UniProtKB/Swiss-Prot entry Q5U9D2, HEPC CANFA, pgs 1-3, 06/28/06	
	N	UniProtKB/Swiss-Prot entry P81172, HEPC HUMAN, pgs 1-3, 06/28/06	
	0	UniProtKB/Swiss-Prot entry Q8MJ80, HEPC PIG, pgs 1-3, 06/28/06	
	Р	UniProtKB/Swiss-Prot entry Q9EQ21, HEPC MOUSE, pgs 1-4, 06/28/06	
	a	ANDREWS, N.C. (2000) Annu, Rev. Genomics Hum. Genet. 1, 75/98	
		1	

Examiner	 Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicants unique clistion designation number (optional). 2 Applicant is to piace a check mark here if Emplah language Translation is statched.
This collection of information is required by 37 CFR 1.94. The information is required to obtain or retain a benefit by the public which is to fie and by the USPTO to process) an application. Confidentially is governed by 35 USP. 6.12 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including garbering, preparing, and authoriting the completed application from the full USPTO. Time will very depending upon the individual case of the process of the complete application from the full USPTO. The will very depending upon the individual case of the complete application from the full USPTO. The visit was represented to take 2 hours to complete, including application. Control of the complete application from the full USPTO. The visit of the process of the individual case of the process of the process of the process of the confidence of the process of

PTO/SB/08B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449	/PTO		Complete if Known		
			Application Number	10/535,608	
INFORMAT	ION DIS	CLOSURE	Filing Date	November 19, 2003	
STATEMENT BY APPLICANT		First Named Inventor	Hasan Kulaksiz		
(Use as many sheets as necessary)			Art Unit	1641	
(Use as many sneets as necessary)		Examiner Name	Gary W. Counts		
Sheet 3	of	5	Attorney Docket Number	26605.00001	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/for country where published.	T ²
	R	PHILPOTT, C.C. (2002) Heatology 35, 993-1001	
	s	BEUTLER ET AL., (2001) Drug?Metab. Dispos. 29, 495/499	
	т	COLLAWN ET AL., (1990) Cell 63, 1061/1072	
	U	KAWABATA ET AL., (1999) J. Biol. Chem. 274, 20826-20832	
	٧	CAMASEHELLA ET AL., (2000) Nat. Genet. 25, 14-15	
	w	FLEMING ET AL., (2002) Proc. Natl. Acad. Sci. USA 99, 10653/10658	
	×	FLEMING ET AL., (2000) Proc. Natl. Acad. Sci. USA 97, 2214/2219	
	Υ	SUBRAMANIAM ET AL., (2002) Cell biochem Biophys. 36, 235/239	
	z	KRAUSE ET AL., (2000) FEBS Lett. 480, 147-150	
	AA	PARK ET AL., (2001 J. Biol. Chem. 276, 7806-7810	

Examiner	Date	1.
Signature	Considere	ed
Oignature	Consider	ou

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to application. I Applicant is upine catation designation on under (optional) 2 Applicant is upine to obtain or retain a benefit by the public which is to the (and, by the USPTO I Applicant is optional to obtain or retain a benefit by the public which is to the (and, by the USPTO to process) an application. Confidentially is applicant to the confidence of the USPTO. Time with vary depending upon the individual case. Any comments on the amount of time you require to complete this form ancier suggestions for reducing this burden, should be sent to the Chef Information Officer, USPTO. The way the purpose of the Chef Information Officer, USPTO and the Applicant of the pour require to complete this form ancier suggestions for reducing this burden, should be sent to the Chef Information Officer, USPTO and the Applicant of the Chef Information Officer, USPTO and the Applicant of the Chef Information Officer, USPTO and the Applicant of the Supposition of the Chef Information Officer, USPTO and the Applicant of the Chef Information Officer, USPTO and the Applicant of the Chef Information Officer, USPTO and the Applicant of the Chef Information Officer, USPTO and the Applicant of the Applicant of the Chef Information Officer, USPTO and the Applicant of the Chef Information Officer, USPTO and the Applicant of the Chef Information Officer, USPTO and the Applicant of the Chef Information Officer, USPTO and the Applicant of the Chef Information Officer, USPTO and the Applicant of the Chef Information Officer, USPTO and the Applicant of the Chef Information Officer, USPTO and the Applicant of the Chef Information Officer, USPTO and the Applicant of the Chef Information Officer, USPTO and the Applicant of the Chef Information Officer, USPTO and the Applicant of the Chef Information Officer, USPTO and the Applicant of the Chef Information Offi Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (09-06) Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Panerwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control purpose.

Substitute for form 1449/PTO		n of Information unless it contains a valid OMB control number. Complete if Known
	Application Number	10/535,608
INFORMATION DISCLOSURE	Filing Date	November 19, 2003
STATEMENT BY APPLICANT	First Named Inventor	Hasan Kulaksiz
(Use as many sheets as necessary)	Art Unit	1641
lose so meny anota as nocessary	Examiner Name	Gary W. Counts
Sheet 4 of 5	Attorney Docket Number	26605.00001

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²
	АВ	NICHOLAS ET AL., (2002) Proc. Natl. Acad. Sci. USA 99, 4396-4601	
	AC	PIGEON ET AL., (2001) J. Biol. Chem. 276, 7811-7819	
	AD	NICOLAS ET AL., (2001) Proc. Natl. Acad. Sci. USA 98, 8780/8785	
	AE	KULAKSIZ ET AL., (2002) Proc. Natl. Acad. Sci. USA 99, 6796-6801	
	AF	KULAKSIZ ET AL., (2002) Am. J. Pathol. 161, 655-664	
	AG	ROST ET AL., (1999) Hepatology 29, 814-821	
	АН	HUNTER ET AL., (2002) J. Biol. Chem., M205305200	
	AI	KAWABATA ET AL., (2000) J. Biol. Chem. 275, 16618-16625	
	AJ	FRAZER ET AL., (2002) Gastroenterology 123, 835-844	
	AK	ADEN ET AL., (1979) Nature 282, 615-616	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Consideration. Include copy of this form with next communication to application.

2. Application replaced market market per life per life per life per life per life.

2. Application replaced market per life per life.

3. Application replaced market per life.

4. Application replaced market per life.

4. Application replaced market per life.

5. Application replace

PTO/SB/08B (09-08)

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO				re required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known	
				Application Number	10/535,608
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Filing Date	November 19, 2003
				First Named Inventor	Hasan Kulaksiz
				Art Unit	1641
				Examiner Name	Gary W. Counts
Sheet	5	of	5	Attorney Docket Number	26605.00001

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹		
	AL	SCHWARTZ ET AL., (1985) EMO J. 4, 899-904	
	АМ	ZHOU ET AL., (1998) Proc. Natl. Acad. Sci. USA 95, 2492-2497	
	AN	LEVY ET AL., (1999) Blood 94, 9-11	
	AO	SANTOS ET AL., (1996) J. Exp. MEd. 184, 1975/1985	
	AP	CAMASEHELLA ET AL., (2000) Nat. Genet. 25, 14-15	
	AQ	ANDERSON ET AL., (2002) Biochem. Soc. Trans. 30, 724-726	

Examiner	Date
Signature	Considered
- 13	Considered

^{*}EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered. Include copy of this form was next communication to apparent.

1. Applicant's to indee cathor designation number (postional). 2. Applicant is not noted in the time of the public which is to the first, including the public which is to the first public which is to the first publication. Confidentially is governed by 33 U.S.C. 122 and 37 CPR 1.14. This collection between the public which is to the first publication from the time of the public which is to the public which is to the public which is the public whic Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.